💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Jury clears J&J of liability in New Jersey talc cancer case

Published 10/11/2018, 03:20 PM
© Reuters. FILE PHOTO: A bottle of Johnson's baby powder is seen in a photo illustration taken in New York
JNJ
-

By Tina Bellon

(Reuters) - A New Jersey jury on Thursday cleared Johnson & Johnson (NYSE:JNJ) of liability in a case involving a woman who alleged that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer.

After less than a day of deliberations, the jury in New Brunswick, New Jersey rejected claims by Rosalind Henry and her husband, who had alleged that Henry's mesothelioma, a cancer associated with asbestos exposure, was caused by the company's talc products.

J&J is facing some 10,600 liability lawsuits across the United States over its talc products, most involving claims that they caused ovarian cancer, and that the company knew of and concealed risks associated with the products.

The company, which is based just a few miles from the courtroom where the latest case took place, said it was pleased with the unanimous jury verdict.

"We have deep sympathy for anyone diagnosed with any form of cancer and appreciate that people are looking for answers. However, Johnson's baby powder is not the cause of this disease," the company said in a statement. It said decades of scientific testing by academic institutions and regulators have shown its talc to be safe and free of asbestos.

A lawyer for Henry did not immediately return a request for comment. During trial, Henry's lawyers said J&J had known for decades about asbestos fibers in its talc, but hid the evidence from regulators and consumers.

J&J has been fighting talc cancer lawsuits for several years, but the litigation shifted in recent months to include allegations of asbestos contamination.

Plaintiffs now claim asbestos fibers in the products are causing both ovarian cancer and mesothelioma.

In April, J&J lost the first trial over such allegations when a jury in New Jersey awarded $117 million to a man suffering from mesothelioma and his wife.

It lost another trial in May, when a California jury awarded $25.7 million to a woman diagnosed with mesothelioma. Both decisions are under appeal.

Since then, the company has had four mistrials in similar cases because jurors could not reach a verdict or because the plaintiff died.

© Reuters. FILE PHOTO: A bottle of Johnson's baby powder is seen in a photo illustration taken in New York

In July, a Missouri jury hit J&J with a massive $4.69 billion verdict in the first trial alleging asbestos contamination has caused ovarian cancer in 22 women. That decision is also under appeal.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.